Bonnie L. Bassler
Known title: DirectorCIK: 0001683607
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Transaction History
| RPRX | ▲ Buy | Grant | 642 | $37K | 9/30/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 689 | $37K | 6/30/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 815 | $37K | 3/31/2026 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,500 | $561K | 1/7/2026 | View on chart |
| REGN | ▼ Sell | Open Market | 1,500 | $1.2M | 1/7/2026 | View on chart |
| REGN | ▲ Buy | Grant | 155 | $0 | 1/2/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 967 | $37K | 12/31/2025 | View on chart |
| REGN | ▲ Buy | Option Exercise | 760 | $282K | 11/20/2025 | View on chart |
| REGN | ▼ Sell | Open Market | 760 | $570K | 11/20/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 1,047 | $37K | 9/30/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 1,064 | $37K | 6/30/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 7,614 | $0 | 5/13/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 1,141 | $37K | 3/31/2025 | View on chart |
| REGN | ▲ Buy | Grant | 166 | $0 | 1/2/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 1,503 | $37K | 12/31/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 1,342 | $37K | 9/30/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 756 | $885K | 8/15/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 756 | $281K | 8/15/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 756 | $843K | 8/2/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 756 | $281K | 8/2/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 1,399 | $37K | 6/28/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 756 | $281K | 6/24/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 756 | $803K | 6/24/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 9,293 | $0 | 6/7/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 827 | $315K | 6/5/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 827 | $836K | 6/5/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 1,240 | $37K | 3/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 854 | $836K | 2/26/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 854 | $335K | 2/26/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 827 | $315K | 1/30/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 827 | $793K | 1/30/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 826 | $315K | 1/3/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 826 | $755K | 1/3/2024 | View on chart |
| REGN | ▲ Buy | Grant | 135 | $0 | 1/2/2024 | View on chart |
| RPRX | ▲ Buy | Grant | 1,353 | $37K | 12/29/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 610 | $230K | 12/13/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 610 | $531K | 12/13/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 1,384 | $37K | 9/29/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 853 | $334K | 8/21/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 853 | $707K | 8/21/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 853 | $673K | 8/10/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 853 | $334K | 8/10/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 1,208 | $37K | 6/30/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 7,747 | $0 | 6/23/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 1,049 | $37K | 3/31/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,240 | $472K | 3/24/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 1,240 | $1.0M | 3/24/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,021 | $389K | 2/3/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 1,021 | $795K | 2/3/2023 | View on chart |
| REGN | ▲ Buy | Grant | 165 | $0 | 1/3/2023 | View on chart |
| RPRX | ▲ Buy | Grant | 943 | $37K | 12/30/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 218 | $83K | 12/8/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 218 | $170K | 12/8/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 913 | $37K | 9/30/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 609 | $229K | 9/9/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 609 | $451K | 9/9/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,279 | $501K | 9/8/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,279 | $902K | 9/8/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,279 | $501K | 9/8/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,279 | $879K | 9/8/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 903 | $37K | 6/30/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 6,328 | $0 | 6/24/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,240 | $472K | 4/7/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,240 | $899K | 4/7/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 964 | $37K | 3/31/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,240 | $472K | 3/30/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,240 | $868K | 3/30/2022 | View on chart |
| REGN | ▲ Buy | Grant | 191 | $0 | 1/3/2022 | View on chart |
| RPRX | ▲ Buy | Grant | 958 | $37K | 12/31/2021 | View on chart |
| RPRX | ▲ Buy | Grant | 992 | $37K | 9/30/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 1,219 | $459K | 8/16/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1,219 | $768K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.